Disappointing first study results of alum-GAD diabetes vaccine in children | ADA
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Why this matters
The vaccine, alum-formulated glutamate decarboxylase (alum-GAD), is being tested in children at high risk of developing type 1 diabetes (T1D), meaning that they have been found to have an ongoing autoimmune process but do not yet have any clinical symptoms of diabetes.
Investigators at Lund University in Sweden recruited 50 participants from the age of four and followed them for five y.
Their goal was to evaluate the safety of two doses of alum-GAD administered subcutaneously to determine if it can delay or prevent the development of T1D.
Levels of GAD autoantibodies increased significantly (P=.0014) ...